Author(s):
D. Roselin Jenifer, B. R. Malathy, Jemmy Christy. H
Email(s):
jeni.christ20@gmail.com
DOI:
10.5958/0974-360X.2020.00016.5 
Address:
D. Roselin Jenifer1*, Dr. B. R. Malathy2, Dr. Jemmy Christy. H3
1Department of Bioinformatics, Faculty of Bio and Chemical Engineering, Sathyabama Institute of Science and Technology, Chennai – 119.
2Department of Microbiology, Reader, Sathyabama Dental College and Hospital, Chennai – 119.
3Assistant Professor, Department of Bioinformatics, Sathyabama Institute of Science and Technology,
Chennai – 119.
*Corresponding Author
Published In:
Volume - 13,
Issue - 1,
Year - 2020
ABSTRACT:
The anticancer activity of secondary metabolites identified from the medicinal plant Plumbago zeylanica was studied using In silico analysis to interpret the inhibitory activity of Matrix metalloproteinases (PDB ID: 3C7X). Polymorphism in Matrix metalloproteinases (MMPs) has been linked to different neoplaplasias, including oral squamous cell carcinoma (OSCC). Docking effect of the 14 secondary metabolites identified from Plumbago zeylanica with receptors was explored. Among the 14 secondary metabolites studied, five of them (Tetradecanal, Sulfurous acid 2-ethylhexyl isohexyl ester, 7, 9 -Di-tert-butyl-1-oxaspiro(4, 5)deca, 1-Fluorononane, Nonadecanol) bind to protein receptors effectively. This was proved by computational modeling based on highest docking score and hydrogen bond interaction.
Cite this article:
D. Roselin Jenifer, B. R. Malathy, Jemmy Christy. H. In Silico Study of secondary metabolites from leaf extract of Plumbago zeylanica. Research J. Pharm. and Tech. 2020; 13(1): 86-90. doi: 10.5958/0974-360X.2020.00016.5
Cite(Electronic):
D. Roselin Jenifer, B. R. Malathy, Jemmy Christy. H. In Silico Study of secondary metabolites from leaf extract of Plumbago zeylanica. Research J. Pharm. and Tech. 2020; 13(1): 86-90. doi: 10.5958/0974-360X.2020.00016.5 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2020-13-1-16